Mesalazine sustained-release tablets    (DrugBank: Mesalazine)

1 disease
IDDisease name (Link within this page)Number of trials
96Crohn disease1

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,209 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02769494
(ClinicalTrials.gov)
March 20169/3/2016The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral UlcerThe Efficacy of Topically Applied Mesalazine Sustained-Release Tablets in Oral Lesions of Crohn's DiseaseCrohn's Disease;Oral UlcerDrug: Mesalazine Sustained-Release Tablets;Drug: Riboflavin Sodium Phosphate InjectionXijing Hospital of Digestive DiseasesNULLRecruiting18 Years65 YearsBoth40Phase 3China